Plain-English translation of NCT07353684 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a new immunotherapy drug—combined with three other medications (, oxaliplatin, and S-1) can shrink advanced stomach or gastroesophageal junction cancer enough that it becomes safe to remove surgically. The study will enroll about 49 people with stomach cancer that currently cannot be operated on but shows promise for becoming operable after treatment.
Many patients with advanced stomach cancer have tumors that are too large or extensive to operate on safely at first. This trial is testing whether this medication combination can shrink tumors enough to make surgery possible, which could offer patients a better chance at cure.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination intravenously and by mouth in repeated 3-week treatment cycles. Every 2 cycles, your doctor will use imaging scans to check whether your tumor is shrinking and becoming operable. If it does, you'll stop one medication, wait 3–6 weeks, and then have surgery. If your tumor doesn't shrink enough after 8 cycles, you'll continue on a maintenance therapy plan. The study lasts several months and involves regular hospital visits, blood tests, and imaging scans.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China